CASE MEDICINE:    HOME
CASE.EDU:    HOME | DIRECTORIES | SEARCH
Case School of Medicine

LEPOW RESEARCH DAY

 
SEARCH CaseMED:

PREVIOUS LEPOW DAY SPEAKERS

2004-2016
2016: Jackson T. Wright, Jr., M.D., Ph.D., FACP, FAHA, FASH

Dr. Jackson T. Wright. Jr. received both his M.D and Ph.D. (Pharmacology) from the University of Pittsburgh and Internal Medicine residency at the University of Michigan.  He has published extensively (over 300 articles, book chapters, and abstracts) and served on many national and international advisory panels.  Among these he served on the National High Blood Education Program Coordinating Committee and co-chaired the treatment section of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the 2014 hypertension guideline published in JAMA and Annals of Internal Medicine.

Dr. Wright's research experience includes having had a major or leadership role in nearly all of the major clinical outcome trials conducted in Black populations over the past two decades.  These include Vice Chair of the African American Study of Kidney Disease in Hypertensives Trial and first authored of its primary results paper, Chair of the Executive Committee for the > 42,000 patient (including 15,000 Blacks) Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT), and lead author on the primary results paper and the papers presenting the results by race. He is also Co-I of one of seven clinical networks in the NIDDK sponsored Chronic Renal Insufficiency Cohort (CRIC) Study (40% Black) and PI of one of the five clinical center networks and 1st author of primary results paper for the NHLBI sponsored Systolic Blood Pressure Intervention Trial (SPRINT).  He was recently honored with the 2015 Clinical Research Award at the national meeting of the American Heart Association and in 2016 with the Scroll of Merit from the National Medical Association, the Maurice Salzman Award, and as a Heath Care Hero by Crain's Cleveland Business Magazine.


2015: Robert F. Siliciano, MD, PhD
Robert Siliciano

Dr. Siliciano is a member of the Howard Hughes Medical Institute and a Professor of Medicine and Molecular Biology and Genetics at the Johns Hopkins University School of Medicine. In 1995, his laboratory provided the first demonstration that latently infected memory CD4+ T cells were present in patients with HIV-1 infection. He went on to characterize this latent reservoir and to show that latently infected cells persist even in patient on prolonged highly active antiretroviral therapy (HAART). These studies indicated that eradication of HIV-1 infection with HAART alone would never be possible, a finding which led to a fundamental change in the treatment strategy for HIV-1 infection. This latent reservoir is now widely recognized as the major barrier to curing HIV-1 infection and is the subject of an intense international research effort. Dr. Siliciano’s laboratory has gone on to characterize the different forms of HIV-1 that persist in patients on HAART and to explore potential strategies for eradicating the virus from this and other reservoirs. In addition, Dr. Siliciano’s recent work has provided a theoretical foundation for the success of antiretroviral therapy in controlling HIV-1 replication.

Dr. Siliciano did his undergraduate work at Princeton University and then received his MD and PhD degrees from Johns Hopkins. After a postdoctoral fellowship at Harvard Medical School, he joined the faculty at Johns Hopkins. He is the recipient of a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation and two NIH Merit Awards. In 2002, he became an Investigator in the Howard Hughes Medical Institute. He is a past Chairman of the NIH AIDS and Related Research Study Section. He currently directs the MD-PhD Program at Johns Hopkins. In 2008, he received a major award in AIDS research, the Bernard N. Fields Memorial Lecture at the Conference for Retroviruses and Opportunistic Infections.


2014: Regina Smith James, MD

Dr. James received her B.S. in psychology/biology from the University of California, Los Angeles (UCLA), and her M.D. from UCLA. Dr. James completed a residency in general psychiatry and child and adolescent psychiatry at the Cleveland Clinic Foundation. She completed a research fellowship in child psychiatry at the Child Psychiatry Branch of the National Institute of Mental Health (NIMH).

Dr. James is the Director of the Office of Health Equity at the Eunice Kennedy Shriver National Institute of Child Health & Human Development at the National Institutes of Health, USA


2013: Barrett J. Rollins, MD, PhD

Barrett J. Rollins, MD, PhD received his undergraduate degree from Amherst College, and his MD and PhD from Case Western Reserve University. He completed his internship and residency in internal medicine at Beth Israel Hospital, Boston. He came to Dana-Farber in 1983, serving first as a clinical, then a postdoctoral research fellow. Since joining the faculty in 1989, Dr. Rollins has worked in the area of inflammation and cancer. He is the Linde Family Professor of Medicine at Harvard Medical School and Chief Scientific Officer at Dana-Farber Cancer Institute. Dr. Rollins' research investigates the effects of inflammation on the development and progression of cancer. His laboratory helped identify the molecular signals that direct the movement and activation of white blood cells during inflammatory responses and discovered that some of these same signals stimulate cancer growth. His group also identified the first genomic abnormality in a rare childhood neoplasm, Langerhans cell histiocytosis.


2012: Arthur Gutierrez-Hartmann, M.D.

Arthur Gutierrez-Hartmann, M.D., is a Professor in the Departments of Medicine and Biochemistry & Molecular Genetics, and Director of the NIH-funded Medical Scientist Training Program (MSTP) at UCHSC. He received a B.A. in Chemistry in 1971 from the University of Texas at Austin. He graduated with an M.D. from the University of Texas Southwestern Medical School in 1975, and he also pursued graduate studies in the Biochemistry Dept at UTSWMS until 1977. From 1977-80, he completed his Internal Medicine residency training at Stanford University Hospital, and from 1980-83, he completed a Molecular Endocrinology training fellowship with Dr. John Baxter at UCSF. After an initial faculty position at UCSF from 1983-85, he was recruited to the University of Colorado HSC (1985), received a PEW Scholars Award (1986-90), and has been a founding member of the M.D./Ph.D. Training Program (1985; now MSTP), the Molecular Biology Graduate Program (1986), the Cancer Center (1987), and the Reproductive Biology Graduate Program (2004). His research is focused on the role of the ETS family of transcription factors in neuroendocrine and epithelial cancers; he Chaired the 2006 Prolactin Family Gordon Research Conference; and he has received several research awards and visiting professorships. As a clinician he attends patients with endocrine disorders and he has been inducted into the American Society of Clinical Investigation.


2011: Speaker event cancelled due to inclement weather

2010: Dr. Christine Seidman

Christine Seidman, M.D. is our speaker and will present a talk titled "Mutations and Mechanisms in Cardiac Hypertrophy.” Christine (Kricket) Seidman is a Professor in the Departments of Medicine and Genetics at Harvard Medical School and Brigham and Women’s Hospital. In 2005, she was named the Thomas W. Smith Professor of Medicine. She is also an Investigator of the Howard Hughes Medical Institute. She was an undergraduate at Harvard College and received an M.D. from George Washington University of Medicine in 1978. Dr. Seidman served as an intern and resident in Internal Medicine at Johns Hopkins Hospital and received subspecialty training in cardiology at the Massachusetts General Hospital. She joined the staff at Brigham and Women’s Hospital in 1987 and is currently the Director of the Cardiovascular Genetics Center. Her research focuses on the discovery of gene mutations that cause human disease, with a focus on cardiovascular conditions such as cardiomyopathy (hypertrophic and dilated), heart failure, and congenital heart malformations. Introductory remarks and her talk will take place from 12:30 1:30 p.m. in the third floor auditorium of the School of Medicine building.


David Altshuler, M.D., Ph. D.

2009: Pamela Davis, MD, Ph.D. Dean, School of Medicine and Vice President for Medical Affairs

"Thinking small: Nanoparticles for gene therapy."

Dr. Davis became the permanent Dean of the School of Medicine in September 2007.  She is also Vice President of Medical Affairs for CWRU. Prior to these appointments, she had been the Interim Dean from September 2006 to September 2007, and prior to that, Vice Dean for Research and, the Chief of the Pediatric Pulmonary Division at Rainbow Babies and Childrens' Hospital, and Professor of Pediatrics, Physiology & Biophysics, and Molecular Biology & Microbiology at Case Western Reserve University. She received the A. B. degree summa cum laude from Smith College, Northampton, MA, and the M.D. and Ph.D. degrees from Duke University. After completing an internship and residency in Medicine at Duke Hospital, she became a Clinical Associate in the Pediatric Metabolism Branch of NIDDK (then NIAMDD) where she received fellowship training in Pulmonary Medicine (via the NHLBI). In 1981, she moved to Case Western Reserve University where she rose through the ranks to her current position.   She now holds the Arline H. and Curtis F. Garvin Research Professorship at Case Western Reserve University.
Dr. Davis is the former director of the Willard A. Bernbaum Cystic Fibrosis Research Center at Case Western Reserve University, which is the site of a Core Center from NIDDK and a Research Development Center for the Cystic Fibrosis Foundation. She has published more than 120 original articles, mostly in the area of cystic fibrosis research, edited one book, contributed numerous book chapters, and served as Associate Editor for several journals.
 
She holds seven U.S. Patents and is a founding scientist of Copernicus Therapeutics, Inc.   She has served on the Advisory Council to NIDDK, on the Board of Scientific Counselors for NHLBI, and on advisory boards for the Burroughs Wellcome Fund and several academic cystic fibrosis centers. She is the recipient of the Rosenthal Prize for academic pediatrics, the Smith College Medal, the Elizabeth A, Rich Award from the American Thoracic Society, the Doris Tulcin Award from the CF Foundation, and has been named regularly in Best Doctors in America and Top Doctors. She was inducted into the Cleveland Medical Hall of Fame.

Her major research interest is in cystic fibrosis, specifically the structure and function of the CFTR molecule, how the cystic fibrosis lung disease arises, and strategies for gene therapy of cystic fibrosis. The interest in the CF lung disease has broadened into a more general interest in lung inflammation, and the strategies she has developed for gene therapy of CF now seem applicable to a broader range of human disease as well.


David Altshuler, M.D., Ph. D.

2008: David Ginsburg, M.D.
James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics
Warner-Lambert/Parke-Davis Professor of Medicine
Member of the Life Sciences Institute at the University of Michigan Medical School

"Disorder of hemostasis due to genes outside of the coagulation system."

Dr. David Ginsburg obtained his B.A. degree in molecular biophysics and biochemistry from Yale University. He went on to earn his M.D. at Duke University, becoming board certified in internal medicine, oncology, hematology, and, later, in genetics. He completed post-doctoral work as a hematology fellow at Harvard University, where he cloned the gene for von Willebrand factor, one of the proteins that is critical to the cascade of reactions causing blood to clot. He continued investigations of the blood-clotting system and disturbances of it in a lab that he launched at University of Michigan, where he remains to this day. He is a member of the National Institute of Medicine and was recently elected to the National Academy of Science for his outstanding contributions to the area of blood coagulation and thrombosis.

Upon starting his research at his University of Michigan lab, Dr. Ginsburg identified subtypes of von Willebrand disease and other clotting conditions, in pursuit of the different mutations in causative genes that could explain variations in the severity of the disorders.  He discovered those genes (LMAN1, MCFD2, and ADAMTS13), but realized that those single genes alone could not explain the clinical course of the illnesses.  This has led him to look for other genes, called modifiers, which might account for disparities in these clotting factor diseases, in part by performing genome-wide studies to search for common clotting factor gene variations.  His most recent work, being conducted as an NIH-funded Howard Hughes Medical Institute investigator, examines the role of plasminogen activators, proteins that turn on the fibrinolytic system, the body’s mechanism for breaking down blood clots.  Dr. Ginsburg’s ongoing research, performed over the last 25 years and counting, has contributed significantly to our understanding of the clotting system and the characterization of coagulation diseases that afflict millions of people.


David Altshuler, M.D., Ph. D.

2007:  Stephen J. Weiss, M.D.
Upjohn Professor of Internal Medicine and Oncology and Chief of Molecular Medicine and Genetics
Department of Internal Medicine
University of Michigan.

“Extracellular matrix remodeling and tumor cell metastases: Chance favors the prepared mind”. 

Dr. Steven Weiss obtained his B.A. degree and his M.D. degree from Ohio State University. He completed his residency in Pathology at Washington University and Barnes Hospital. He was a research fellow in the Division of Hematology/Oncology at the University of Michigan Medical Center. Following his fellowship, he joined the faculty where he is now the E. Gifford and Love Barnett Upjohn Professor of Internal Medicine and Oncology. He also serves as Chief of Molecular Medicine and Genetics.

Dr. Weiss’ research examines the mechanisms used by normal and neoplastic cells to remodel the extracellular matrix during many pathological events, ranging from cell differentiation and tissue morphogenesis to tumor cell metastasis. His current interests include the regulation of epithelial-mesenchymal cell transformation and the function of membrane-type matrix metalloproteinases during development and neoplasia. His contributions have been published in many outstanding journals, including Science, Nature, Cell, the New England Journal of Medicine, the Journal of Clinical Investigation, the Journal of Experimental Medicine, and the Proceedings of the National Academy of Science USA. Dr. Weiss serves on the editorial boards for many journals, including a five-year term as the editor-in-chief of the Journal of Clinical Investigation. He has been funded by the NIH to pursue his research interests for over 20 years and has received an NIH MERIT Award. He is a member of the American Society for Clinical Investigation and the American Association of Physicians. In 2001, he was elected to membership in the Institute of Medicine of the National Academies.


David Altshuler, M.D., Ph. D.

2006:  David Altshuler, M.D., Ph.D.
Professor of Genetics and Medicine
Harvard Medical School
Director, Program in Medical and Population Genetics
The Broad Institute, MIT

“Human Genome Sequence Variation and the Inherited Basis of Disease”. 

David Altshuler obtained his B.S. degree from MIT and his M.D. and Ph.D. in Genetics from Harvard Medical School.  He completed his internship and residency in Medicine at Massachusetts General Hospital, as well as his clinical fellowship in endocrinology.   He was a post-doctoral fellow at the Whitehead Institute at MIT.  He is a founding member of the Broad Institute at MIT, where he presently directs the Program in Medical and Population Genetics.  He is also an attending physician in the Diabetes Unit at Massachusetts General Hospital.  His research interests are in the study of human genetic variation and its application to disease, using tools and information from the Human Genome Project.  He is particularly interested in diabetes mellitus, and has identified a common genetic variant that increased the risk of developing type 2 diabetes. These studies provide an approach for analyzing the role of common genetic variations in disease.


Helen H. Hobbs, M.D.

2005: Helen H. Hobbs, M.D.
Professor of Internal Medicine and Molecular Genetics Director of the Eugene McDermott Center for Human Growth and Development University of Texas Southwestern Medical Center

“Genetic Protection against Cholesterol Accumulation and Atherosclerosis”

Helen H. Hobbs obtained her M.D. degree from Case Western Reserve School of Medicine. She completed her internship in Internal Medicine at Columbia-Presbyterian Hospital in New York and her residency at Parkland Memorial Hospital in Dallas. She was Chief Resident in the Department of Internal Medicine at the University of Texas Southwestern Medical Center at Dallas. She was a Post-doctoral Fellow and Endocrinology Fellow in the Department of Molecular Genetics at the University of Texas Southwestern and subsequently joined the faculty. She is presently Professor of Internal Medicine and Molecular Genetics and Director of the Eugene McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. She also directs the Donald W. Reynolds Cardiovascular Clinical Research Center. She is a Howard Hughes Investigator.

Dr. Hobbs’ research interests are in defining the genetic determinants of plasma cholesterol levels, with an emphasis on the atherogenic lipoproteins and lipid transport. The central theme of her work is how dysregulation in the uptake and trafficking of dietary lipids contribute to human diseases, particularly coronary atherosclerosis and the metabolic syndrome. Her contributions work has been published in many outstanding journals, including Science, Proceedings of the National Academy of Science USA, the Journal of Clinical Investigation, the Journal of Biological Chemistry, the American Journal of Physiology: Endocrinology and Metabolism, and the American Journal of Cardiology. Dr. Hobbs is a member of the Institute of Medicine. She is also an elected member of the Association of American Physicians and the American Society of Clinical Investigation.


David T. Scadden, M.D.

2004: David T. Scadden, M.D.
Professor of Medicine, Harvard Medical School Director, Center for Regenerative Medicine, Massachusetts General Hospital Boston, MA.

“What Bone Does for Bone Marrow”

David T. Scadden received his M.D. degree from Case Western Reserve School of Medicine. Following his internship and residency at the Brigham and Women’s Hospital in Boston, he completed a Clinical Fellowship in Medicine and in Hematology/Oncology at the Harvard Medical School, the Brigham and Women’s Hospital, and the Dana-Farber Cancer Institute. Subsequently, he was a Research Fellow at these institutions working with James M. Cunningham and later at the New England Medical Center working with Robert S. Schwartz and John M. Coffin. He joined the faculty at Harvard University as an Instructor and is presently Professor of Medicine at the Harvard Medical School and Director of the Center of Regenerative Medicine at Massachusetts General Hospital.

Dr. Scadden’s research interests are focused on the bone marrow and stem cell biology. He is particularly interested in the regulation of entry and exit from the cell cycle, as this has important implications for expansion of stem cells and gene transduction. He is also interested in the regulation of stem cell localization to and within specific microenvironments and the interactions of stem cells with elements of the microenvironmental niche. These studies are critically important in understanding how stem cells develop and how they may function in regenerative processes in many organs. His work has been published in many outstanding journals including Nature, Nature Medicine, Science, Nature Biotechnology, Proceedings of the National Academy of Science USA, the Journal of Clinical Investigation, the Journal of Immunology and Blood. He has received many honors, including elected membership in the American Society for Clinical Investigation and the Association of American Physicians. He serves on the editorial boards for many journals including Blood, Stem Cells, and Experimental Hematology, and he is an Associate Editor for Blood.